Prescient Therapeutics Limited (ASX:PTX)

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Other Revenue	3.02	3.71	2.43	1.89	1.19	1.03
Revenue	3.02	3.71	2.43	1.89	1.19	1.03
Revenue Growth (YoY)	-2.96%	52.89%	28.52%	59.37%	15.17%	-37.53%
Gross Profit	3.02	3.71	2.43	1.89	1.19	1.03
Selling, General & Admin	4.1	3.71	3.2	2.82	2.29	1.55
Research & Development	4.63	6.97	6.22	3.4	2.49	2.76
Operating Expenses	8.83	10.9	9.89	7.1	5.43	4.49
Operating Income	-5.81	-7.19	-7.46	-5.21	-4.24	-3.46
Interest Expense	-0.01	-	-	-0.01	-0.01	-0
Interest & Investment Income	0.51	0.69	0.46	0.04	0.07	0.07
Currency Exchange Gain (Loss)	-0.03	-0.02	-0.01	0.06	-0.01	0.03
EBT Excluding Unusual Items	-5.35	-6.52	-7	-5.12	-4.2	-3.37
Asset Writedown	-1.72	-1.72	-	-	-	-
Other Unusual Items	-	-	-	-	0.05	0.05
Pretax Income	-7.07	-8.24	-7	-5.12	-4.15	-3.32
Net Income	-7.07	-8.24	-7	-5.12	-4.15	-3.32
Net Income to Common	-7.07	-8.24	-7	-5.12	-4.15	-3.32
Shares Outstanding (Basic)	805	805	728	648	612	394
Shares Outstanding (Diluted)	805	805	728	648	612	394
Shares Change (YoY)	2.10%	10.69%	12.31%	5.88%	55.18%	61.22%
EPS (Basic)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-9.7	-7.4	-6.19	-4.32	-3.97	-2.32
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-192.44%	-193.58%	-307.14%	-275.75%	-357.80%	-336.62%
Profit Margin	-233.95%	-221.91%	-288.47%	-270.85%	-349.97%	-322.65%
Free Cash Flow Margin	-321.17%	-199.28%	-254.97%	-228.50%	-335.08%	-225.11%
EBITDA	-5.81	-7.19	-7.46	-5.21	-4.24	-3.46
EBITDA Margin	-192.43%	-193.56%	-	-275.68%	-	-
D&A For EBITDA	0	0	0	0	0	0
EBIT	-5.81	-7.19	-7.46	-5.21	-4.24	-3.46
EBIT Margin	-192.44%	-193.58%	-	-275.75%	-	-

Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.